David P. Halstead, Ph.D.

Representative Experience

• Represented Proteolix, Inc. on intellectual property matters from their inception until their acquisition in 2009 by Onyx Pharmaceuticals for $276M in cash and up to $575M of additional performance-based payments. In addition to drafting and prosecuting the extensive, global patent portfolio that protected Proteolix’s key products, including the drug now known as carfilzomib (Kyprolis®), David also helped Proteolix navigate due diligence with various potential investors, partners, and acquirors.
• Represents public biotech companies on a variety of intellectual property matters, drafting and prosecuting a broad patent portfolio covering diverse biotech and pharmaceutical technologies, including overseeing various successful European and Australian oppositions, managing relationships with collaborators, obtaining creative reach-through claims in both the US and Europe, and successfully defending these claims in a European opposition.
• Represents global pharmaceutical companies, regularly advising them on business-critical issues from identifying and overcoming potential freedom-to-operate issues for biotech, pharmaceutical and consumer health product candidates to the handling of double-patenting issues with minimum impact on exclusivity expiration. In one exemplary project, David advised on the complex interplay of FDA labeling requirements, patent exhaustion, and inducement of patent infringement.
• Represents publicly-held companies that develop drug delivery technologies, advising on strategies for navigating competitor patents while simultaneously structuring patent portfolios to maximize exclusive market space and gain leverage in potential licensing negotiations.
• Represents investors in life science companies, helping them understand the patent portfolios that protect the value of their investments and analyze complex intellectual property disputes such as European oppositions & interferences.